<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01673724</url>
  </required_header>
  <id_info>
    <org_study_id>SKL001</org_study_id>
    <nct_id>NCT01673724</nct_id>
  </id_info>
  <brief_title>Pramipexole and Bromocriptine on Nonmotor Symptoms of Early Parkinson's Disease</brief_title>
  <official_title>Effect of Pramipexole and Bromocriptine on Nonmotor Symptoms of Early Parkinson's Disease: Multicenter, Open-label, Parallel, Randomized Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sandoz</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sandoz</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether pramipexole and bromocriptine are effective
      in the treatment of non-motor symptoms in Parkinson's Disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE Evaluate the Improvement of Nonmotor symptom scale (NMSS) between
      Pramipexole and Bromocriptine for early Parkinson's disease during 24-week treatment

      SECONDARY OBJECTIVE

        -  Evaluate the improvement for Depression which is one of the Nonmotor symptoms

        -  Evaluate the improvement of clinical symptoms between two groups

        -  Evaluate the improvement of Quality of Life between two groups
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">May 23, 2016</completion_date>
  <primary_completion_date type="Actual">May 23, 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>K-NMSS</measure>
    <time_frame>24 weeks</time_frame>
    <description>Evaluate The total and each category score of K-NMSS</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>K-MADRS</measure>
    <time_frame>24 weeks</time_frame>
    <description>Evaluate the Improvement of the depression refering to the total score of K-MADRS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>UPDRS I/II/III</measure>
    <time_frame>24 weeks</time_frame>
    <description>Evaluate the improvement of UPDRS I/II/III</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>K-PDQ39</measure>
    <time_frame>24 weeks</time_frame>
    <description>Evaluate the improvement of Patient's QOL</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">121</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>pramipexole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dosage form: tablet dosage: pramipexole 0.125/0.25/0.5/1mg frequency: tid duration: 24weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bromocriptine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>bromocriptine dosage form: white round tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pramipexole</intervention_name>
    <description>pramipexole</description>
    <arm_group_label>pramipexole</arm_group_label>
    <other_name>Sandoz Pramipexole</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bromocriptine</intervention_name>
    <description>bromocriptine</description>
    <arm_group_label>Bromocriptine</arm_group_label>
    <other_name>Parlodel tab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Parkinson's disease patients in accordance with UK Queensquare Brain Bank

          -  modified Hoehn &amp; Yahr stage &lt;3

          -  Dopamine agents(Levodopa, dopamine agonists) naive patients, or the patients who have
             discontinued the agents at least four weeks before the screening in case of using the
             dopamine agents are administered before.

        Exclusion Criteria:

          -  K-MMSE&lt;24

          -  History of drug-induced Parkinsonism

          -  secondary parkinsonism

          -  History of schizophrenia or hallucination

          -  Requirement of treatment with anti-depressants due to depressive disorder

          -  Pregnant and/or breeding women

          -  Renal inadequacy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seongbeom Koh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Korea University Guro Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Korea University Ansan Hospital</name>
      <address>
        <city>Ansan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inje University Busan Paik Hospital</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Youngnam University Hospital</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kangwon Nat'l University Hospital</name>
      <address>
        <city>Kangwon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inje university Sanggye Paik Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea University Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 23, 2012</study_first_submitted>
  <study_first_submitted_qc>August 23, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 28, 2012</study_first_posted>
  <last_update_submitted>September 14, 2017</last_update_submitted>
  <last_update_submitted_qc>September 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pramipexole</mesh_term>
    <mesh_term>Bromocriptine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

